Bimagrumab
What do these badges mean?
Evidence tier
- AHuman-validated — Human trials showing positive results and good safety.
- BAnimal-grade — No human trials yet, but solid animal/preclinical evidence of effect and safety.
- CAnecdotal — No human or animal trials — only anecdotal/observational reports.
- DInsufficient evidence — No or insufficient evidence (encyclopedia only — never recommended by the builder).
Safety light
- 🟢 Green — Only mild, manageable side effects; reasonable safety data.
- 🟡 Yellow — Needs active management, has a meaningful contraindication/interaction, or has thin long-term data.
- 🔴 Red — Risk of a hospital-level event — treat with serious caution.
Browse-only — not on the protocol builder's curated shortlist, so the builder won't recommend it.
What is it?
Bimagrumab is the drug that does, with a single monthly injection, what every gym bro since the 1990s wished a needle could do: strip fat and add muscle at the same time. In the cleanest trial to date it produced ~20% body-weight loss where 93% of what came off was fat and lean muscle mass was fully preserved — a body-composition result that no GLP-1 alone gets close to.
The honest framing first, because OHM doesn’t fudge categories: bimagrumab is not a peptide. Most of what this site covers: BPC-157, the GLP-1s, the GH secretagogues — are peptides (short amino-acid chains) or small molecules. Bimagrumab is a monoclonal antibody: a large, lab-engineered version of the same Y-shaped immune protein your body makes, designed to latch onto one specific target and block it. That’s why it’s dosed monthly by infusion/injection in a clinic rather than self-administered like a peptide — antibodies are big, fragile, cold-chain biologics. It earns a page here anyway because it’s the most important molecule in the conversation OHM cares about most: fat loss without muscle loss.
Its target is the activin type II receptor (ActRII) — the docking station on muscle cells for the body’s two main “stop growing” signals, myostatin and activin. Block that receptor and you take the brakes off muscle. The result is muscle gain plus, as a bonus that surprised researchers, a large drop in fat mass. (See Follistatin 344 for the body’s natural version of this same brake-release, and the The 2026 GLP-1 pipeline — Dulaglutide, Liraglutide, Semaglutide, Tirzepatide, CagriSema, Mazdutide, MariTide, Pemvidutide, Petrelintide, VK2735, Orforglipron, Survodutide, Eloralintide, Retatrutide overview for where bimagrumab sits in the broader weight-loss landscape.)
Bimagrumab was originally a Novartis asset, spun out into a startup called Versanis Bio, which Eli Lilly acquired in 2023 (deal completed August 14, for up to $1.925 billion). So when you see “Lilly’s muscle-preservation antibody,” that’s the lineage.
What does it do in my body?
The whole story is about brakes on muscle growth — the pathway Dr. Alex Tatem maps cleanly in his muscle-drug-landscape video, and the same one that explains Follistatin 344:
The baseline. Your body’s default is to keep building muscle. Three signals control how much.
- Myostatin — the main muscle-growth brake. It’s mostly skeletal-muscle-specific, which is why blocking it is relatively clean. (This is the brake the bodybuilding community has chased for 25 years.)
- Activin — a related brake, but expressed system-wide. It also regulates wound healing, inflammation, and reproductive hormones (FSH). Block activin everywhere and you get off-target effects: bleeding, skin issues, healing problems. This is the reason muscle drugs in this class are tricky.
- The receptor both use: ActRII. Both myostatin and activin deliver their “stop growing” message by docking on the activin type II receptor.
What bimagrumab does. Rather than mopping up myostatin or activin in the bloodstream, bimagrumab plugs the receptor itself. It binds ActRII (both the A and B subtypes) and blocks it, so neither myostatin nor activin can deliver its signal (mechanism described in PMID 39385353, the investigational-drug review, and PMID 33439265). With the brakes off:
- Muscle grows — skeletal muscle hypertrophies (the trials measured real lean-mass gains, not just preservation).
- Fat drops — the surprise. Blocking ActRII also drives a large reduction in fat mass, including visceral (organ) fat. The leading mechanistic read is that the bigger, more metabolically active muscle plus altered adipose signaling shifts the body toward burning fat.
Why this matters for the GLP-1 era. GLP-1 drugs (Semaglutide, Tirzepatide, Retatrutide) are spectacular at removing weight: but a chunk of that weight is muscle. The peer-reviewed review the KB already cites (Stefanakis/Mantzoros 2024, PMID 39481534) puts it plainly: over 25% of the weight lost on incretin drugs is typically fat-free mass, including skeletal muscle. Bimagrumab attacks a completely different lever than a GLP-1 — appetite/intake on one side, muscle-growth brakes on the other — which is exactly why combining the two is so interesting.
How can it help me?
- Best fit: Conceptual: anyone on a GLP-1 who wants to understand the muscle-preservation problem. There is no consumer access — this is a trial drug
- Where the science stands: Two completed phase 2 RCTs (JAMA Netw Open 2021; Nature Medicine 2026 BELIEVE) + an investigational-drug review; no phase 3, no approval
The full evidence — every human, animal, and lab study, graded — is one tap away: use the See the deeper science → toggle at the top.
Is it dangerous? What are the side effects?
The activin-pathway side-effect class is the honest caveat for this whole drug category. From the phase 2 data:
- Diarrhea — among the most common adverse events with bimagrumab in the trials (PMID 33439265).
- Muscle spasms / cramps — reported in the bimagrumab arms.
- Pancreatitis signal in the combination data. The BELIEVE combo arm flagged a pancreatitis signal worth watching — partly the known GLP-1 class concern, possibly compounded by the antibody.
- Activin-blockade off-target risks (class-level). Because bimagrumab blocks the shared ActRII receptor, the theoretical concerns from suppressing activin system-wide are bleeding events, impaired wound healing, skin changes, and reproductive-hormone effects. Bimagrumab’s measured profile looked cleaner than Regeneron’s activin-antibody triplet, but the class risk is the reason this molecule isn’t trivially safe.
- Class-risk comparator: the Regeneron COURAGE triplet (trevogrumab + garetosmab + semaglutide) safety profile is materially worse than the bimagrumab + semaglutide doublet. Phase 2 COURAGE 26-week interim results (EASD 2025; Regeneron press release Sept 2025):
- AE-driven discontinuations: 30.9% in the triplet arm (trevogrumab + garetosmab + semaglutide) vs 4.6% with semaglutide alone — a ~7× increase.
- Muscle spasm: 40.9% in the triplet arm vs 4.6% with semaglutide alone.
- Two deaths in the triplet group: one cardiac arrest in a patient with prior cardiovascular disease, one undetermined-cause death in a patient with multiple cardiovascular risk factors. Regeneron has stated no causal association has been identified between the drugs and these events, but the signal is in the public dataset and worth surfacing honestly.
- Lower-intensity arms (trevogrumab + semaglutide without garetosmab) looked much closer to the semaglutide-alone safety profile (4.7% AE-driven discontinuation at 200 mg trevogrumab, 10.6% at 400 mg), so the safety story tracks dose + activin-antibody count, not just the class. The garetosmab addition is what tips the AE profile over.
- Takeaway: activin-blockade as a class is a real safety tail; the bimagrumab approach (single antibody to the shared ActRII receptor) is the cleaner version. The triplet arm of COURAGE is the worked example of “more aggressive activin blockade = worse AE profile that may not be worth the marginal lean-mass gain.”
- Injection/infusion-related reactions — as with any antibody biologic.
Bimagrumab is not a stimulant and carries no dependence/withdrawal pattern. The real-world reason most people will never take it is access, not tolerability: it’s a trial drug.
Regulatory status:
- NOT FDA-approved for any indication. Bimagrumab is investigational — no marketing authorization anywhere for obesity or muscle wasting.
- Not commercially available. There is no legitimate over-the-counter, “research-use-only,” or compounded path. Anyone selling “bimagrumab” to consumers is outside how this drug is legitimately supplied (and an antibody is far harder to counterfeit credibly than a peptide).
- Development status: Novartis-origin → Versanis Bio → acquired by Eli Lilly, completed Aug 14 2023 (up to $1.925B). The completed BELIEVE phase 2b (with semaglutide) read out positively at ADA June 2025 and published in Nature Medicine 2026. In September 2025, Lilly withdrew a separate planned bimagrumab + tirzepatide phase 2b for “strategic business reasons” — widely read as Lilly redirecting resources toward its oral GLP-1, orforglipron. Whether bimagrumab advances to phase 3 is, as of this writing, unresolved.
- History: bimagrumab was previously studied (and failed primary endpoints) in muscle-wasting conditions like sporadic inclusion-body myositis and sarcopenia before the obesity body-composition findings redirected it.
Typical dosing
Talk to your medical provider before starting any protocol. That said, here are the doses most people commonly use — shared for educational purposes so you can have an informed conversation. These peptides are sold for research use only and are not FDA-approved drugs, and this isn't medical advice.
There is no at-home protocol: and that’s the honest answer. Unlike the peptides covered elsewhere on this site, you cannot reconstitute a vial of bimagrumab. It is a large antibody given as an intravenous or subcutaneous infusion/injection, roughly monthly, under medical supervision in a trial setting. The trial doses ranged up to 30 mg/kg in the high-dose BELIEVE combination arm (PMID 41772149). That’s it — the rest of any “protocol” is the foundation that is in your control.
What you can actually do today for the same goal (fat loss without muscle loss):
- Resistance training, 2–3×/week minimum. Tatem’s verbatim, lift-it-directly line: “The best myostatin inhibitor remains the same as it was in 1975. Heavy squats and enough protein to kill a small horse.” This is the foundation thesis — the drug is the last 10%, the lifting is the 90%.
- Protein: ~1 g per pound of goal body weight (1.6–2.2 g/kg). Adequate protein is the single biggest dietary lever against lean-mass loss on any weight-loss intervention.
- If you’re on a GLP-1 (Semaglutide, Tirzepatide, Retatrutide): the BELIEVE data is the reason to not run it bare. Pair it with the foundation above, and the GH-axis adjuvants that are accessible — MK-677 (Ibutamoren) (oral GH secretagogue) or CJC-1295/Ipamorelin — are the practical, available stand-ins for the muscle-preservation job bimagrumab does in the trial.
- Slow your weight loss down. Rapid loss costs more lean mass. Slower titration + protein + lifting preserves more of it without any exotic drug.
What should I avoid combining — and what's synergistic?
Bimagrumab doesn't have a dedicated stacking protocol in our notes — the interactions that matter most are in the safety section above. For how people combine it with other peptides, the deeper-science view has the full detail.
How can I buy this?
We don't have a verified affiliate source for Bimagrumab yet, so there's no coupon or vendor link here — we won't point you to a seller we haven't vetted. When buying any research-use-only peptide, the single biggest variable is the supply chain: insist on a vendor that publishes third-party Certificates of Analysis (COAs) confirming identity and >99% purity. Working with a peptide-literate clinician is one solid route — see our provider directory — or check back as our verified sources list grows.
| Class | Fully human monoclonal antibody (IgG1) — not a peptide. Blocks the activin type II receptor (ActRII A and B) |
| Mechanism (one line) | Binds and blocks ActRII → shuts off myostatin + activin signaling (the muscle-growth brakes) → muscle gain + fat loss |
| Originator | Developed by Novartis; spun out to Versanis Bio; acquired by Eli Lilly (deal completed Aug 14 2023, up to $1.925B) |
| Route / frequency | Intravenous or subcutaneous infusion/injection given in clinical trials — monthly dosing in the phase 2 work |
| Strongest result | Phase 2b BELIEVE (bimagrumab + semaglutide, n=507): combo lost −20.2% body weight with 92.8% of the loss from fat and lean mass fully preserved vs. 7.4% lean loss on semaglutide alone (PMID 41772149) |
| Earlier result | Phase 2 in T2D+obesity (n=75, 48 wk): −20.5% body fat, +3.6% lean mass vs. placebo (PMID 33439265) |
| Evidence base | Two completed phase 2 RCTs (JAMA Netw Open 2021; Nature Medicine 2026 BELIEVE) + an investigational-drug review; no phase 3, no approval |
| Safety signal | Diarrhea and muscle spasms most common; pancreatitis signal noted in the combo data — see Side effects |
| Regulatory status | Investigational: NOT FDA-approved for any indication. Not commercially available. Lilly withdrew a planned bimagrumab+tirzepatide phase 2b in Sept 2025 (“strategic business reasons”) |
| Alyve product | None. Not a peptide, not a research-use-only compound, not an Alyve SKU. Encyclopedia entry only |
| Best-fit user | Conceptual: anyone on a GLP-1 who wants to understand the muscle-preservation problem. There is no consumer access — this is a trial drug |
What it is
Bimagrumab is the drug that does, with a single monthly injection, what every gym bro since the 1990s wished a needle could do: strip fat and add muscle at the same time. In the cleanest trial to date it produced ~20% body-weight loss where 93% of what came off was fat and lean muscle mass was fully preserved — a body-composition result that no GLP-1 alone gets close to.
The honest framing first, because OHM doesn’t fudge categories: bimagrumab is not a peptide. Most of what this site covers: BPC-157, the GLP-1s, the GH secretagogues — are peptides (short amino-acid chains) or small molecules. Bimagrumab is a monoclonal antibody: a large, lab-engineered version of the same Y-shaped immune protein your body makes, designed to latch onto one specific target and block it. That’s why it’s dosed monthly by infusion/injection in a clinic rather than self-administered like a peptide — antibodies are big, fragile, cold-chain biologics. It earns a page here anyway because it’s the most important molecule in the conversation OHM cares about most: fat loss without muscle loss.
Its target is the activin type II receptor (ActRII) — the docking station on muscle cells for the body’s two main “stop growing” signals, myostatin and activin. Block that receptor and you take the brakes off muscle. The result is muscle gain plus, as a bonus that surprised researchers, a large drop in fat mass. (See Follistatin 344 for the body’s natural version of this same brake-release, and the The 2026 GLP-1 pipeline — Dulaglutide, Liraglutide, Semaglutide, Tirzepatide, CagriSema, Mazdutide, MariTide, Pemvidutide, Petrelintide, VK2735, Orforglipron, Survodutide, Eloralintide, Retatrutide overview for where bimagrumab sits in the broader weight-loss landscape.)
Bimagrumab was originally a Novartis asset, spun out into a startup called Versanis Bio, which Eli Lilly acquired in 2023 (deal completed August 14, for up to $1.925 billion). So when you see “Lilly’s muscle-preservation antibody,” that’s the lineage.
How it works
The whole story is about brakes on muscle growth — the pathway Dr. Alex Tatem maps cleanly in his muscle-drug-landscape video, and the same one that explains Follistatin 344:
The baseline. Your body’s default is to keep building muscle. Three signals control how much.
- Myostatin — the main muscle-growth brake. It’s mostly skeletal-muscle-specific, which is why blocking it is relatively clean. (This is the brake the bodybuilding community has chased for 25 years.)
- Activin — a related brake, but expressed system-wide. It also regulates wound healing, inflammation, and reproductive hormones (FSH). Block activin everywhere and you get off-target effects: bleeding, skin issues, healing problems. This is the reason muscle drugs in this class are tricky.
- The receptor both use: ActRII. Both myostatin and activin deliver their “stop growing” message by docking on the activin type II receptor.
What bimagrumab does. Rather than mopping up myostatin or activin in the bloodstream, bimagrumab plugs the receptor itself. It binds ActRII (both the A and B subtypes) and blocks it, so neither myostatin nor activin can deliver its signal (mechanism described in PMID 39385353, the investigational-drug review, and PMID 33439265). With the brakes off:
- Muscle grows — skeletal muscle hypertrophies (the trials measured real lean-mass gains, not just preservation).
- Fat drops — the surprise. Blocking ActRII also drives a large reduction in fat mass, including visceral (organ) fat. The leading mechanistic read is that the bigger, more metabolically active muscle plus altered adipose signaling shifts the body toward burning fat.
Why this matters for the GLP-1 era. GLP-1 drugs (Semaglutide, Tirzepatide, Retatrutide) are spectacular at removing weight: but a chunk of that weight is muscle. The peer-reviewed review the KB already cites (Stefanakis/Mantzoros 2024, PMID 39481534) puts it plainly: over 25% of the weight lost on incretin drugs is typically fat-free mass, including skeletal muscle. Bimagrumab attacks a completely different lever than a GLP-1 — appetite/intake on one side, muscle-growth brakes on the other — which is exactly why combining the two is so interesting.
What the research shows
Two completed phase 2 RCTs anchor everything. Both are real, both are web-verified.
Phase 2, type-2 diabetes + obesity (the proof-of-concept) — Heymsfield SB et al., JAMA Network Open 2021 (PMID 33439265):
- n=75 randomized (37 bimagrumab, 38 placebo); 48 weeks; both arms got diet + exercise counseling.
- Bimagrumab vs. placebo: −20.5% vs −0.5% total body fat mass; +3.6% vs −0.8% lean mass; −6.5% vs −0.8% body weight; plus a significant drop in HbA1c (better blood sugar).
- The headline that made the field pay attention: a monthly antibody that simultaneously dropped fat ~20%, added lean mass, and improved glycemic control.
Phase 2b BELIEVE: bimagrumab + semaglutide (the one everyone cites) — Heymsfield SB et al., Nature Medicine 2026 (PMID 41772149); presented at the ADA 85th Scientific Sessions, Chicago, June 2025:
- n=507 adults with overweight/obesity; randomized across multiple arms (placebo, bimagrumab alone, semaglutide alone, and combinations); 72-week data.
- High-dose combination (bimagrumab 30 mg/kg + semaglutide 2.4 mg): −20.2% body weight (≈24.2 kg), vs −14.8% for semaglutide alone and −10.8% for bimagrumab alone.
- Body-composition split: the whole point: 92.8% of the combination’s weight loss was fat, vs 71.8% on semaglutide alone.
- Lean mass: fully preserved in the combo (no change vs. control), while semaglutide alone lost 7.4% lean mass, and bimagrumab alone gained 2.5% lean mass.
- Total body fat reduction: −45.7% combo vs −27.8% semaglutide-alone. Visceral fat: −58.2% combo vs −35.8% semaglutide-alone.
Note on the early-circulating numbers: a “22.1% body weight / 70–75% fat on Sema alone” framing appears in the source video digest (captured before the paper published). The peer-reviewed Nature Medicine figures are −20.2% combo weight loss, 92.8% fat in combo, 71.8% fat on semaglutide alone — use the published numbers. The video’s direction was right; the exact figures are now pinned to the paper.
The practical translation for OHM’s audience. If ~25–30% of GLP-1 weight loss can be muscle, then the combo data quantifies the prize: a person who’d lose ~7% of their lean mass on semaglutide alone lost none of it with the antibody added. That is the single most useful fact a GLP-1 user can take from this whole pathway — and it’s the mechanistic case for the muscle-preservation foundation (resistance training + protein) and the GH-axis adjuvant peptides (MK-677 (Ibutamoren), CJC/Ipamorelin) that are accessible today.
The investigational-drug review — Vana V et al., 2024 (PMID 39385353): a published overview of bimagrumab as an investigational anti-ActRII antibody for obesity; confirms mechanism, the phase 2 results, and the open questions (durability, long-term safety, where it fits vs. incretins).
Where experts read it differently
- “Is this the holy grail, or a sidelined science project?” Tatem’s read (empowering, foundation-first): the trial data is genuinely exciting and validates that muscle loss on GLP-1s is a real, quantifiable problem — but Big Pharma keeps shelving these muscle drugs, so don’t wait for a pill that may never ship. The conventional read: bimagrumab is a promising phase 2 asset whose path to market is uncertain, and oral GLP-1s (orforglipron) are where the commercial momentum is. Both are looking at the same facts. OHM sides with Tatem’s framing — the foundation does the muscle-preservation work today; the antibody, if it ever arrives, is the last 10%.
- Myostatin-only vs. activin-blocking: the safety fork. The “holy grail” some researchers want is pure myostatin inhibition (clean, muscle-specific). Bimagrumab blocks the shared receptor, so it dials down activin too: which is why the side-effect conversation (below) is real and not hand-waving. Experts split on whether the body-composition prize is worth the system-wide activin blockade. Regeneron’s parallel COURAGE triplet (trevogrumab + garetosmab + semaglutide) reportedly preserved muscle but drove higher discontinuation, skin problems, and bleeding events — “activin-blocking is nasty business,” in Tatem’s words. Bimagrumab’s profile looked cleaner than that, but the same class concern applies.
- Why did Lilly pull back if the data is this good? Tatem’s theory (compelling, not confirmed): Lilly is consolidating R&D behind orforglipron, its oral small-molecule GLP-1: a pill that ships in a cardboard box with no needles and no cold chain, vs. an expensive cold-chain antibody. In September 2025 Lilly withdrew a planned bimagrumab + Tirzepatide phase 2b trial for “strategic business reasons” (the trial was withdrawn before enrolling patients) — note this is a different study from the completed BELIEVE semaglutide trial above. The honest reading: the muscle-preservation problem on GLP-1s is real and pharma takes it seriously, but Big Pharma is not on track to solve it with an antibody in the next 2–3 years. That leaves the foundation + accessible adjuvants as the practical answer.
Real-world protocol
The doses and schedules here are for educational and informational purposes only. Bimagrumab is an investigational monoclonal antibody that is not FDA-approved and not commercially available: there is no consumer or DIY protocol. The “protocol” below describes how it was given in clinical trials, for understanding only. This is not medical advice, and there is no verified-vendor or research-use-only source for this drug. Consult a qualified physician for anything related to weight-loss medication.
There is no at-home protocol: and that’s the honest answer. Unlike the peptides covered elsewhere on this site, you cannot reconstitute a vial of bimagrumab. It is a large antibody given as an intravenous or subcutaneous infusion/injection, roughly monthly, under medical supervision in a trial setting. The trial doses ranged up to 30 mg/kg in the high-dose BELIEVE combination arm (PMID 41772149). That’s it — the rest of any “protocol” is the foundation that is in your control.
What you can actually do today for the same goal (fat loss without muscle loss):
- Resistance training, 2–3×/week minimum. Tatem’s verbatim, lift-it-directly line: “The best myostatin inhibitor remains the same as it was in 1975. Heavy squats and enough protein to kill a small horse.” This is the foundation thesis — the drug is the last 10%, the lifting is the 90%.
- Protein: ~1 g per pound of goal body weight (1.6–2.2 g/kg). Adequate protein is the single biggest dietary lever against lean-mass loss on any weight-loss intervention.
- If you’re on a GLP-1 (Semaglutide, Tirzepatide, Retatrutide): the BELIEVE data is the reason to not run it bare. Pair it with the foundation above, and the GH-axis adjuvants that are accessible — MK-677 (Ibutamoren) (oral GH secretagogue) or CJC-1295/Ipamorelin — are the practical, available stand-ins for the muscle-preservation job bimagrumab does in the trial.
- Slow your weight loss down. Rapid loss costs more lean mass. Slower titration + protein + lifting preserves more of it without any exotic drug.
Side effects & management
The activin-pathway side-effect class is the honest caveat for this whole drug category. From the phase 2 data:
- Diarrhea — among the most common adverse events with bimagrumab in the trials (PMID 33439265).
- Muscle spasms / cramps — reported in the bimagrumab arms.
- Pancreatitis signal in the combination data. The BELIEVE combo arm flagged a pancreatitis signal worth watching — partly the known GLP-1 class concern, possibly compounded by the antibody.
- Activin-blockade off-target risks (class-level). Because bimagrumab blocks the shared ActRII receptor, the theoretical concerns from suppressing activin system-wide are bleeding events, impaired wound healing, skin changes, and reproductive-hormone effects. Bimagrumab’s measured profile looked cleaner than Regeneron’s activin-antibody triplet, but the class risk is the reason this molecule isn’t trivially safe.
- Class-risk comparator: the Regeneron COURAGE triplet (trevogrumab + garetosmab + semaglutide) safety profile is materially worse than the bimagrumab + semaglutide doublet. Phase 2 COURAGE 26-week interim results (EASD 2025; Regeneron press release Sept 2025):
- AE-driven discontinuations: 30.9% in the triplet arm (trevogrumab + garetosmab + semaglutide) vs 4.6% with semaglutide alone — a ~7× increase.
- Muscle spasm: 40.9% in the triplet arm vs 4.6% with semaglutide alone.
- Two deaths in the triplet group: one cardiac arrest in a patient with prior cardiovascular disease, one undetermined-cause death in a patient with multiple cardiovascular risk factors. Regeneron has stated no causal association has been identified between the drugs and these events, but the signal is in the public dataset and worth surfacing honestly.
- Lower-intensity arms (trevogrumab + semaglutide without garetosmab) looked much closer to the semaglutide-alone safety profile (4.7% AE-driven discontinuation at 200 mg trevogrumab, 10.6% at 400 mg), so the safety story tracks dose + activin-antibody count, not just the class. The garetosmab addition is what tips the AE profile over.
- Takeaway: activin-blockade as a class is a real safety tail; the bimagrumab approach (single antibody to the shared ActRII receptor) is the cleaner version. The triplet arm of COURAGE is the worked example of “more aggressive activin blockade = worse AE profile that may not be worth the marginal lean-mass gain.”
- Injection/infusion-related reactions — as with any antibody biologic.
Bimagrumab is not a stimulant and carries no dependence/withdrawal pattern. The real-world reason most people will never take it is access, not tolerability: it’s a trial drug.
Regulatory status
- NOT FDA-approved for any indication. Bimagrumab is investigational — no marketing authorization anywhere for obesity or muscle wasting.
- Not commercially available. There is no legitimate over-the-counter, “research-use-only,” or compounded path. Anyone selling “bimagrumab” to consumers is outside how this drug is legitimately supplied (and an antibody is far harder to counterfeit credibly than a peptide).
- Development status: Novartis-origin → Versanis Bio → acquired by Eli Lilly, completed Aug 14 2023 (up to $1.925B). The completed BELIEVE phase 2b (with semaglutide) read out positively at ADA June 2025 and published in Nature Medicine 2026. In September 2025, Lilly withdrew a separate planned bimagrumab + tirzepatide phase 2b for “strategic business reasons” — widely read as Lilly redirecting resources toward its oral GLP-1, orforglipron. Whether bimagrumab advances to phase 3 is, as of this writing, unresolved.
- History: bimagrumab was previously studied (and failed primary endpoints) in muscle-wasting conditions like sporadic inclusion-body myositis and sarcopenia before the obesity body-composition findings redirected it.
How to access it
You can’t: and that’s the straight answer. Bimagrumab is an investigational monoclonal antibody available only inside clinical trials. Unlike the peptides this site covers (which have a research-use-only or compounding lane) and unlike the prescription GLP-1s like Tirzepatide (available via clinicians and compounding pharmacies), bimagrumab has no consumer route at all:
- No FDA approval → no prescription path, brand-name or compounded.
- No research-use-only / verified-vendor catalog product → it’s a complex biologic, not a peptide you can reconstitute, and not an Alyve SKU. Anyone advertising “bimagrumab for sale” is selling something you should not trust.
- No affiliate or coupon path → this is an encyclopedia entry, full stop. (Contrast with the accessible muscle-preservation tools — see below.)
The legitimate ways to encounter it are (1) enrolling in a clinical trial if one is recruiting (check clinicaltrials.gov), or (2) waiting to see whether Lilly advances it to approval — uncertain after the September 2025 strategic pullback.
What to do instead, today. The goal bimagrumab chases — losing fat while keeping muscle — is achievable right now with tools that are accessible:
- The foundation: resistance training + ~1 g/lb protein. This does most of the work; the BELIEVE trial itself can’t beat the basics it was layered on top of.
- Accessible adjuvants when you want the extra GH-axis support during a fat-loss phase: MK-677 (Ibutamoren) (oral GH secretagogue) and CJC-1295/Ipamorelin are the practical, available stand-ins. See the The 2026 GLP-1 pipeline — Dulaglutide, Liraglutide, Semaglutide, Tirzepatide, CagriSema, Mazdutide, MariTide, Pemvidutide, Petrelintide, VK2735, Orforglipron, Survodutide, Eloralintide, Retatrutide overview for how these fit alongside a GLP-1.
- A peptide-literate clinician if you’re running a GLP-1 and want help building the muscle-preservation side of the protocol properly.
Sources
- Dr. Alex Tatem’s muscle-drug-landscape digest: the myostatin/activin/follistatin pathway map, the BELIEVE-trial framing, the Lilly/orforglipron strategic-pullback theory, the COURAGE-triplet comparison, and the “1975 heavy squats” foundation line.
- (PMID 39481534, Stefanakis/Mantzoros 2024, Metabolism) — the lean-mass-loss-on-incretins review that quantifies the >25%-fat-free-mass problem and names bimagrumab/trevogrumab as muscle-preserving pipeline agents.
- Follistatin C/yellow grading; class context for the activin-blocking biologics (Bimagrumab/Trevogrumab/Garetosmab; BELIEVE/COURAGE).
- Heymsfield SB et al., JAMA Network Open 2021 — phase 2 bimagrumab in T2D+obesity, n=75, −20.5% fat / +3.6% lean. 33439265. https://pubmed.ncbi.nlm.nih.gov/33439265/
- Heymsfield SB et al., Nature Medicine 2026 — the BELIEVE trial — bimagrumab + semaglutide, n=507, −20.2% weight / 92.8% fat / lean preserved. 41772149. https://pubmed.ncbi.nlm.nih.gov/41772149/
- Vana V et al., 2024: review: “Bimagrumab: an investigational human monoclonal antibody against activin type II receptors for treating obesity.” 39385353. https://pubmed.ncbi.nlm.nih.gov/39385353/
- Lilly–Versanis acquisition (completed Aug 14 2023, up to $1.925B) and Sept 2025 bimagrumab+tirzepatide phase 2b withdrawal — Lilly investor releases + NCT05616013 (BELIEVE) on ClinicalTrials.gov.
Related: The 2026 GLP-1 pipeline — Dulaglutide, Liraglutide, Semaglutide, Tirzepatide, CagriSema, Mazdutide, MariTide, Pemvidutide, Petrelintide, VK2735, Orforglipron, Survodutide, Eloralintide, Retatrutide · Retatrutide · Tirzepatide · Semaglutide · Follistatin 344 · MK-677 (Ibutamoren).
Sources & references
- Dr. Alex Tatem’s muscle-drug-landscape digest: the myostatin/activin/follistatin pathway map, the BELIEVE-trial framing, the Lilly/orforglipron strategic-pullback theory, the COURAGE-triplet comparison, and the “1975 heavy squats” foundation line.
- (PMID 39481534, Stefanakis/Mantzoros 2024, Metabolism) — the lean-mass-loss-on-incretins review that quantifies the >25%-fat-free-mass problem and names bimagrumab/trevogrumab as muscle-preserving pipeline agents.
- Follistatin C/yellow grading; class context for the activin-blocking biologics (Bimagrumab/Trevogrumab/Garetosmab; BELIEVE/COURAGE).
- Heymsfield SB et al., JAMA Network Open 2021 — phase 2 bimagrumab in T2D+obesity, n=75, −20.5% fat / +3.6% lean. 33439265. https://pubmed.ncbi.nlm.nih.gov/33439265/
- Heymsfield SB et al., Nature Medicine 2026 — the BELIEVE trial — bimagrumab + semaglutide, n=507, −20.2% weight / 92.8% fat / lean preserved. 41772149. https://pubmed.ncbi.nlm.nih.gov/41772149/
- Vana V et al., 2024: review: “Bimagrumab: an investigational human monoclonal antibody against activin type II receptors for treating obesity.” 39385353. https://pubmed.ncbi.nlm.nih.gov/39385353/
- Lilly–Versanis acquisition (completed Aug 14 2023, up to $1.925B) and Sept 2025 bimagrumab+tirzepatide phase 2b withdrawal — Lilly investor releases + NCT05616013 (BELIEVE) on ClinicalTrials.gov.
Related: The 2026 GLP-1 pipeline — Dulaglutide, Liraglutide, Semaglutide, Tirzepatide, CagriSema, Mazdutide, MariTide, Pemvidutide, Petrelintide, VK2735, Orforglipron, Survodutide, Eloralintide, Retatrutide · Retatrutide · Tirzepatide · Semaglutide · Follistatin 344 · MK-677 (Ibutamoren).